Global Pretest Probability Study of Coronary Artery Disease
NCT ID: NCT05722145
Last Updated: 2025-12-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
100000 participants
OBSERVATIONAL
2022-11-25
2027-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study will investigate multiple international cohorts of patients referred for noninvasive testing using coronary CTA or other non-invasive imaging modalities. Locally-calibrated PTP models in consideration of risk factors or CAC will be separately tailored to each different cohort, and will be evaluated.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Multi-modal Adverse Events Prediction for Premature Coronary Heart Disease Trial: MAP-CHD Trial
NCT07004452
Galectin-3 Binding Protein in Cardiovascular Disease and Chronic Heart Failure
NCT01210157
Personalized Risk Evaluation and Diagnosis (Using Corus CAD or ASGES) in the Coronary Tree
NCT00500617
Prediction of Primary Cardiovascular Events Using the Multimarker Approach
NCT05704569
Coronary Artery Calcium, Exercise Tests, and CHD Outcome
NCT00005562
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The data collected will include risk factors and demographics such as age, sex, ethnicity, hypertension, smoking, diabetes, dyslipidemia and family history of CAD. Outcomes such as death and myocardial infarctions will be included in the dataset if available. All data received will be anonymized and de-identified. Study team members will check through the study data to ensure that all study data is accurately collected and complete.
The data elements of different cohorts may not harmonize or match with each other. There could be missing data elements or different data inputs. As such, omission or imputation may be used to perform analyses. To minimize data heterogeneity in format, sites will be provided with a standard template and data dictionary. This will complete the initial data harmonization and expected data elements. The collected dataset would then be harmonized by the biostatistics team prior to analysis.
The approximate total study size n = 100,000. Assuming an area under the receiver operating curve (AUC) of 0.70 for existing PTP and CAC methods, this proposal is adequately powered to detect an increase of 0.05 in AUC using a two-sided z-test at a significance level of 0.05. Continuous variables will be expressed as mean and standard deviation. Categorical variables will be expressed as absolute numbers and percentages. Distributions will be tested for normality using Shapiro-Wilk statistics. Non-normally distributed variables will be represented as median with 25th to 75th interquartile range. Comparison of normally distributed continuous variables will be performed using Student's t test for paired and unpaired data. Non-normally distributed variables will be compared using Mann-Whitney Rank Sum tests and Kruskal-Wallis tests. Comparison of categorical data will be performed using Chi-square and Fisher's Exact Tests where appropriate.
Differences in outcomes over time will be analyzed by the Kaplan-Meier analysis with log-rank test for each outcome. Using Cox regressions analysis univariate and multivariate regression analyses will be performed. Univariate analysis will include pre-event variables with p values \<0.10. Variables that showed a significant (p\<0.05) correlation with the endpoints, after univariate analysis, will be considered in the multivariate models. Odds ratios and 95% confidence interval will be calculated. Statistical significance was established as p\<0.05. Advanced machine learning techniques (e.g. neural networks) may be applied.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The subjects need to have underwent computed tomography angiography (CTA) or non-contrast computer tomography (NCCT) for assessment of coronary artery disease.
Exclusion Criteria
* Subjects who are unable to undergo cardiac CT
21 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Heart Centre Singapore
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lohendran Baskaran
Role: PRINCIPAL_INVESTIGATOR
National Heart Centre Singapore
Pamela Douglas
Role: STUDY_CHAIR
Duke University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Heart Centre Singapore
Singapore, Singapore, Singapore
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-2521
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.